BioDirection Chooses Albuquerque, New Mexico, for Manufacturing Complex
"We anticipate that our new facility will be fully operational within the next several months," said Sharad Joshi, President & CEO of BioDirection. "The plant is a critical step in our commercialization of the Tbit™ System. We have elected to establish in-house manufacturing to ensure our first product meets all targeted criteria for consistency and reproducible quality. Timing is critical since we anticipate entering the European market in 2020 and the U.S. market by the middle of 2020 following FDA clearance."
"Our cutting-edge technology delivers a test result in 90 seconds from a finger stick of blood, potentially opening the door to a large number of markets including sports and recreation venues, military training and deployment, senior living facilities and hazardous work environments. The Tbit System is a truly disruptive technology,” he added.
The company's Tbit System is based on a proprietary nanotechnology biosensor to rapidly detect and accurately measure protein biomarkers that are released from the brain immediately following a head trauma or jolt to the body. The portable system allows for testing to be initially performed in the emergency department and eventually, after receipt of further FDA clearances, at the point of injury. Early diagnosis of a brain injury can support more appropriate treatment decisions while potentially reducing unnecessary head CT scans.
Sweden-based Volvo Construction Equipment Adds Shippensburg, Pennsylvania, Training Complex
“Made in America” Executive Order to Affect International Companies and FDI
Trends in Office and Industrial Parks
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Another Look at Rural Economies
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Supply Chain Execs Respond as Pandemic Creates E-Commerce Surge